FDA Clarifies Orphan-Drug Exclusivity Following Catalyst Pharms., Inc. v. Becerra Decision

Summary

The US FDA has clarified its approach to orphan-drug exclusivity following a recent court ruling in Catalyst Pharms., Inc. v. Becerra, which found that FDA must set aside its approval of Jacobus Pharmaceutical Company's drug.